

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

Odyssey CLx

RRID:SCR_014579

Type: Tool

Proper Citation

Odyssey CLx (RRID:SCR_014579)

Resource Information

URL: https://www.licor.com/bio/products/imaging_systems/odyssey/

Proper Citation: Odyssey CLx (RRID:SCR_014579)

Description: A data analysis software developed to simplify and record data from fluorescent related assays such as Western Blots, EMSAs, and Western Assays. This software will consolidate all of the resulting data into one easy-to-track image, and thus removes the need for multiple exposures, as well as standardizing the resulting fluorescent bands without image saturation, blowout, or removed sensitivity. Odyssey CLx is capable of scanning multiple mini-blots, microplates, or slides at the same time.

Synonyms: Odyssey CLx Imaging System

Resource Type: software resource, software application, data analysis software, data processing software

Keywords: data analysis software, data processing software, fluorescence, software, band, image saturation, single image, western blot, emsa, western assay, image tracking, data simplification, sensitivity

Availability: Commercial, Paired with a Scanning System

Resource Name: Odyssey CLx

Resource ID: SCR_014579

License: Commercial

License URLs: https://www.licor.com/corp/terms_conditions.html

Record Creation Time: 20220129T080321+0000

Record Last Update: 20260808T190026+0000

Ratings and Alerts

No rating or validation information has been found for Odyssey CLx.

No alerts have been found for Odyssey CLx.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 137 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Telonis AG, et al. (2026) Synergistic intragenic epigenetic deregulation by IDH2 and SRSF2 mutations causes mis-splicing of key transcriptional regulators. Science advances, 12(1), eadu8292.

Ziegler Y, et al. (2026) JAK/STAT1-interferon-ISGylation networks in breast cancer resistance to inhibitors of FOXM1 and CDK4/6. NPJ breast cancer, 12(1).

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. Cancer discovery, 16(5), 895.

Gea-González A, et al. (2026) Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer's disease patients. Alzheimer's research & therapy, 18(1).

Lee S, et al. (2026) Functional characterization of SDHB variants clarifies hereditary pheochromocytoma and paraganglioma risk and genotype-phenotype relationships. The Journal of clinical investigation, 136(4).

O'Callaghan B, et al. (2026) Glucose concentration of neuronal media formulations influences PINK1-dependent mitophagy in human iNeurons. Autophagy reports, 5(1), 2685472.

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. Molecular cancer therapeutics, 25(1), 156.

Magrinelli F, et al. (2026) Variants in the proteasome regulator PSMF1 cause a phenotypic spectrum from parkinsonism to perinatal lethality. Nature communications, 17(1).

Vilarrubi A, et al. (2026) SMARCB1 Deficiency in Tumors Confers a Vulnerability to H3K27 Demethylase Inhibitors via Autophagy Disruption. Cancer research.

Orkwis JA, et al. (2026) Helminth proteins recapitulate key structural motifs of MIF to facilitate immunomodulation of host receptors. iScience, 29(7), 116513.

Wei H, et al. (2026) PDCD5 promotes substrate release from the TRiC complex in cilia and flagella. Molecular cell.

Elhaw AT, et al. (2026) RHOV Is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis. *Cancer research*, 86(11), 2623.

Ma B, et al. (2026) MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer. *Molecular cancer research : MCR*.

Pawar NR, et al. (2026) A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells. *Molecular cancer therapeutics*.

Bhagwat SV, et al. (2025) Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degradar with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer. *Cancer research*, 85(4), 777.

Landi D, et al. (2025) A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. *Cancer research communications*, 5(3), 527.

Sheth AS, et al. (2025) PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia. *Cancer research communications*, 5(4), 648.

Crawford KJ, et al. (2025) Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. *Molecular cancer*, 24(1), 208.

Zidel A, et al. (2025) Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer. *Scientific reports*, 15(1), 16964.

Puzio-Kuter AM, et al. (2025) Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. *Cancer discovery*, 15(6), 1159.